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Plackett–BurmanAbstract Two new stability-indicating liquid chromatographic methods using two detectors, an
ultraviolet (UV) and a charged aerosol detector (CAD) simultaneously connected in series were val-
idated for the assessment of lisdexamfetamine dimesylate (LDX) in capsule. The method was opti-
mized and the inﬂuence of individual parameters on UV and CAD response and sensitivity was
studied. Chromatography was performed on a Zorbax CN column (250 mm · 4.6 mm, 5 lm) in
an isocratic elution mode, using acetonitrile and 20 mM ammonium formate at pH 4.0 (50:50,
v/v) as mobile phase and UV detection at 207 nm. The developed method was validated according
to ICH guidelines and the parameters’ speciﬁcity, limit of detection, limit of quantitation, linearity,
accuracy, precision and robustness were evaluated. CAD is designated to be a non-linear detector in
a wide dynamic range, however, the method was linear over the concentration range of 70–
130 lg mL1 in both detectors. The method was precise and accurate. Robustness study was per-
formed by a Plackett–Burman design, delivering results within the acceptable range. Neither the
excipients nor the degradation products showed interference in the method after studies of speci-
ﬁcity as well as under stress conditions. The results of the LC-UV and LC-CAD methods were
Figure 1 Chemical structure of lis
S1906 G. Carlos et al.statistically compared through ANOVA and showed no signiﬁcant difference (p> 0.05). Both pro-
posed methods could be considered interchangeable and stability-indicating, and can be applied as
an appropriate quality control tool for routine analysis of LDX in capsule.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Attention-deﬁcit/hyperactivity disorder (ADHD) is the most
prevalent neurobehavioral disorder in childhood (American
Academy of Pediatrics, 2000) and it is characterized by symp-
toms such as inattention, impulsivity and hyperactivity that
can impact on many aspects of behavior and performance at
school and at home (American Psychiatric Association,
1994). The prevalence of the disorder has been investigated
worldwide. Different prevalence rates reﬂect methodological
differences (population sampled, study design, source of infor-
mation, age, diagnostic criteria used, or how they are applied)
more than cultural differences in diagnosis of the disorder.
Using criteria of DSM-IV, the ADHD affects 3–6% of chil-
dren around the globe (Faraone et al., 2003; Rohde et al.,
1999).
Stimulants are generally considered as ﬁrst-line medication
for the treatment of ADHD (Banaschewski et al., 2004).
Nevertheless, short-acting stimulants need of multiple daily
dosing and concerns about their abuse potential have led to
the development of alternative agents (Pliszka and The
AACAP Work Group on Quality Issues, 2007).
Lisdexamfetamine dimesylate (LDX) (Fig. 1), the ﬁrst member
of a new class of prodrug stimulants, was developed with the
objective to obtain long term action for the treatment of
ADHD in children and adults, improving adherence and low-
ering abuse potential (Jasinski and Krishnan, 2009; Mickle
et al., 2006). LDX consists of d-amphetamine covalently
bound to the essential amino acid l-lysine. After oral adminis-
tration, the pharmacologically active d-amphetamine is
released when the covalent bond is cleaved during metabolism
(Mickle et al., 2006).
Quality, safety and effectiveness are the most important
attributes of pharmaceutical products. Therefore, the develop-
ment of analytical methodology to quality control has a funda-
mental role since it provides an evaluation of the drug
regarding its identity, strength, purity and stability during shelf
life (Jain and Basniwal, 2013).
High-performance liquid chromatography (HPLC) is the
technique most commonly used for the quantitation of drugs
in formulation. Many detector types are usually combined
with a preliminary separation by HPLC (Watson, 2005).
Ultraviolet (UV) detection is the most widely used detection
method for HPLC due to its high sensitivity, broad linear
range, easy operation, relatively low cost and other advan-
tages, as well as its compatibility with the most mobile phase
solvents in both isocratic and gradient elution modesdexamfetamine dimesylate.(Shaodong et al., 2010; Vervoort et al., 2008). The charged
aerosol detector (CAD) was introduced by Dixon and
Peterson (Dixon and Peterson, 2002) and it belongs to the
group of universal detectors, which operate independently of
the physicochemical and spectral properties of non-volatile
analytes and many semivolatile analytes. This includes those
without chromophores and those that do not ionize, which
can be detected routinely with charged aerosol detector, thus
providing a consistent response (Dixon and Peterson, 2002;
Nova´kova´ et al., 2009). CAD system has also other positive
characteristics such as a broad dynamic response range with
high sensitivity, good precision for a wide range of analytes,
and a simple and reliable operation (Gamache et al., 2005).
Gas inlet pressure and the signal output range are the few con-
trollable parameters that CAD merely requires (Vehovec and
Obreza, 2010).
There are not at the moment in the reviewed literature ana-
lytical methods available for the quantitative analysis of LDX
for raw material and pharmaceutical products. There are some
studies describing the determination of LDX and its metabo-
lite in biological ﬂuids using a HPLC coupled to tandem mass
spectrometry (LC–MS–MS) (Biederman et al., 2007; Boellner
et al., 2010; Ermer et al., 2012, 2011a, 2011b, 2010; Jasinski
and Krishnan, 2009; Krishnan and Moncrief, 2007; Krishnan
and Zhang, 2008; Krishnan et al., 2008; Pennick, 2009,
2010). However, LC–MS–MS require more expensive equip-
ment making it less suitable for routine analysis of LDX
capsules.
As a way of contributing to its improved quality control
and ensuring therapeutic efﬁcacy of LDX, this study aims
for the development and validation of two new stability-
indicating liquid chromatographic methods for the determina-
tion of LDX in capsules using UV and CAD detectors. The
results generated were compared.
Forced degradation studies provide data to support the
identiﬁcation of possible degradants, degradation pathways
and intrinsic stability of the drug molecule and validation of
stability indicating analytical procedures (ICH, 2003). As
CAD is a universal detector, it was used to verify whether
CAD could have advantages over UV detector for the control
of LDX degradation products.2. Materials and methods
2.1. HPLC instrumentation
Assays were carried out using a Shimadzu LC system (Kyoto,
Japan), equipped with a LC-20AT pump, DGU-14A degasser,
CTO-10A column oven, SPD-10A UV detector and Corona
CAD detector from ESA Bioscience, Inc. (Chelmsford, MA,
USA), were connected in series.
Peak purity was assessed using a Shimadzu chromato-
graphic system (Kyoto, Japan) equipped with LC-20AT pump,
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CTO-10A column oven, and a Rheodyne 7725i manual injec-
tor were used.
2.2. Materials
LDX standard was obtained in our laboratory. Modiﬁed crys-
tallization technique was used to extract LDX standard from
capsules. LDX standard was identiﬁed by infrared spec-
troscopy, 1H NMR, 13C NMR and LC-ESI-QTOF and its
purity was determined by mass balance (99.56%). The purity
found can be considered satisfactory according to WHO
(2006). The capsules (Venvanse) labeled to contain 70 mg
of the LDX were purchased at the local market. HPLC-
grade acetonitrile (R1) was obtained from Tedia (Fairﬁeld,
OH, USA). All chemicals used were of pharmaceutical or spe-
cial analytical grade.
2.3. Chromatographic conditions
The chromatography was performed using a Zorbax CN col-
umn, 250 mm · 4.6 mm, 5 lm (Agilent Technologies, USA)
in the isocratic elution mode constituted of the acetonitrile
and 20 mM ammonium formate at pH 4.0, adjusted with
2 M formic acid (50:50, v/v). The ﬂow rate was
1.0 mL min1 and the column temperature, 25 C. The buffer
was ﬁltered through a 0.45 lm membrane ﬁlter (Millipore,
Bedford, MA, USA). The injection volume was 20 lL for both
standard and samples. Detection was performed using a CAD
at a gas pressure of 35 psi in the 100 pA detection range and
the UV detector was set at 207 nm. The output signal was pro-
cessed using Chromeleon 6.8 (Dionex Corporation) software.
2.4. Preparation of reference solution
The stock solution of LDX was prepared by dissolving the
respective standard substance in methanol to obtain a concen-
tration of 0.5 mg mL1. The stock solution was stored under
refrigeration (5 C), protected from light, and daily diluted to
an appropriate concentration in the mobile phase to yield ﬁnal
concentrations of 70, 80, 90, 100, 110, 120 and 130 lg mL1.
2.5. Preparation of sample solutions
To prepare the sample solution, twenty capsules containing
70 mg of LDX were opened and the contents were mixed.
An appropriate amount was transferred into an individual
50 mL volumetric ﬂask, diluted to volume with methanol,
and ﬁltered through a 0.45 mm membrane ﬁlter (Millipore,
Bedford, MA, USA), obtaining the ﬁnal concentration of
0.5 mg mL1 of the active pharmaceutical ingredient. This
solution was diluted to the ﬁnal concentration of
100 lg mL1 in mobile phase.
2.6. Validation
The methods using UV and CAD detectors were validated for
linearity, speciﬁcity, precision, accuracy, and robustness fol-
lowing the International Conference on Harmonization(ICH) requirements (ICH, 2005). The robustness study was
performed by a Plackett–Burman design.
2.6.1. Linearity
Linearity was determined by constructing three analytical
curves, in three different days, each one with seven reference
concentrations of LDX in the range of 70–130 lg mL1 pre-
pared by the dilution of appropriate amounts of standard
stock solution with mobile phase. To verify the reproducibility
of the detector response, triplicate 20 lL injections were made
for the standard solution at each concentration level. The peak
areas were plotted against the respective concentrations to
obtain the analytical curve. The results were tested by analysis
of variance (ANOVA) and the goodness of regression model
was evaluated by correlation coefﬁcient regression signiﬁcance,
lack-of-ﬁt and residuals analysis. Residuals were examined to
verify normality, no autocorrelation and homoscedasticity
(equality or homogeneity of variance).
2.6.2. Speciﬁcity
The method speciﬁcity was assessed through the inﬂuence of
excipients by comparing the chromatograms obtained from
LDX and the blank composed by excipients mixture (micro-
crystalline cellulose, croscarmellose and magnesium stearate)
present in capsule formulation, without the drug.
To assess the stability-indicating capability of the method
by UV and CAD detectors, LDX standard and drug product
solutions (500 lg mL1) were subjected to stress testing the
same manner. Acidic, basic, thermal, oxidative, and photolytic
conditions were evaluated.
Hydrolytic studies: Acidic conditions were obtained by
treating the solutions with 1 M formic acid at room tempera-
ture (20 ± 2 C) for 24 h and under reﬂux, in silicone bath
at 100 C for 3 h. The studies in alkaline conditions were done
similarly using ammonium hydroxide.
Oxidative studies: Oxidative conditions were obtained by
treating the solutions with 3%, 5% and 8% hydrogen peroxide
at room temperature for 24 h and 8.0% hydrogen peroxide,
under reﬂux, in silicone bath at 100 C for 3 h.
Photolytic studies: Solutions were submitted to pho-
todegradation in a UV light chamber (1.0 · 0.17 · 0.17 m) at
long wave ultraviolet light (352 nm) for 24 h and short wave
ultraviolet light (254 nm) for 8 h at room temperature. The
chamber wall was covered with mirrors, in order to distribute
the light uniformly and equipped with a UV-A lamp
(Blacklight blue lamp – Orion, 30 W, 130 V– 352 nm) and
UV-C lamp (Light express LE UV, 30 W–254 nm).
Thermal studies: Thermal degradation was evaluated sub-
jecting the solutions to 60 C for 24 h and to 100 C for 6 h,
under reﬂux and protected from light.
In every case control solutions without the stressing agents
were evaluated.
Before the solutions were assessed in HPLC, they were
diluted with mobile phase to 100 lg mL1 and pH was
adjusted to 4.0 with ammonium hydroxide and formic acid
on samples subjected to acid and alkaline conditions,
respectively.
Peak purity was assessed using HPLC with diode array
detector. Equipment and chromatographic conditions used
were described in Sections 2.1 and 2.3.
Table 1 Factors and levels used in evaluating the robustness
of methods.
Factors Levels
Optimal Low High
Flow (mL min1) 1 0.9 1.1
Organic concentration (%) 50 47 53
Ammonium formate (mM) 20 18 22
pH 4.0 3.8 4.2
Temperature (C) 25 20 30
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The determination of repeatability of the method (intraday)
and intermediate precision (interday) were evaluated.
Repeatability was calculated by carrying out six independent
samples containing 100 lg mL1 of LDX, prepared as
described in Section 2.5, during the same day, under the same
experimental conditions. Intermediate precision was studied byFigure 2 Inﬂuence of excipients: Chromatograms of ultraviolet (A) a
reference solution 100 lg mL1; (2) placebo.performing the same procedure on 3 different days. The rela-
tive standard deviations (RSD) of the peaks were calculated.
2.6.4. Accuracy
The accuracy of the method was performed by adding known
amounts of reference standard solution in the sample solution
and it was determined at three concentrations (80, 100 and
120 lg mL1) corresponding to 80%, 100%, and 120% of
the nominal analytical concentration. Each level was made in
triplicate. Accuracy was calculated as the percentage of the ref-
erence standard recovered.
2.6.5. Limit of detection and limit of quantitation
Limit of detection (LOD) and limit of quantitation (LOQ) for
LDX were evaluated using the mean values of three indepen-
dent analytical curves. Detection and quantitation limits were
determined by a linear regression model, using the following
equations: LOD= (3.3 · r)/S; LOQ= (10 · r)/S, where 3.3
and 10 correspond to the factors of detection and quantitationnd charged aerosol (B) detectors. (1) Lisdexamfetamine dimesylate
Figure 3 Chromatograms obtained after oxidation (8% H2O2, reﬂux, silicone bath at 100 C, 4 h): (A) ultraviolet and (B) charged
aerosol detectors. Peaks (1) and (2) are degraded forms and peak (LDX) is lisdexamfetamine dimesylate.
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and S is the slope obtained in the linearity study of the method
(ICH, 2005).
2.6.6. Robustness
ICH described robustness of an analytical procedure as a mea-
sure of its capacity to remain unaffected by small, but deliber-
ate variations in method parameters and provides an
indication of its reliability during normal usage [28]. The abil-
ity of methods LC-CAD and LC-UV to perform effectively
was measured employing a Plackett–Burman design to show
their robustness. Plackett–Burman design is the so-called
two-level screening design which allows screening a relatively
large number of factors in a relatively small number of exper-
iments (Vander Heyden et al., 2001). The factors investigated
were buffer concentration and pH (ammonium formate), tem-
perature of column oven, organic phase concentration (ace-
tonitrile) and ﬂow rate. Each factor consists of one high and
one low levels. The factors’ levels investigated in robustness
evaluation are reported in Table 1. The factors combinations
were calculated through software Minitab (v.16) in 12 exper-
iments and the results were assessed using the same software.
The methods were evaluated through assay of LDX capsule,using standard solution in the same experimental condition.
In a manner to lessen the effects of extraneous or uncontrol-
lable conditions that can impact the results of an experiment,
the design was randomized regarding the order in which exper-
imental runs were performed.
2.7. Comparison of methods
Method comparison experiment should be considered when
one wants to evaluate the equivalence of different methods
that are used for the same intent. According to USP, the com-
parison of two methods determines whether their average
results or their variability differs by an amount that is deemed
important. Method equivalence could be assessed by the anal-
ysis of precision, whether the two methods have ‘‘comparable’’
precision (United States Pharmacopoeia, 2011).
Then, UV and CAD RP-LC methods were compared with
each other by applying paired Student’s t test for comparing
averages and signiﬁcant differences were evaluated at the
95% conﬁdence level. According to Borman et al. (2009), the
results are paired if the same sample is analyzed in different
methods and they are independent if different samples are pre-
pared for each method. Thereby, our data were considered
Figure 4 Chromatograms after exposure to UV light – 254 nm, 8 h: (A) ultraviolet detector (B) Charged aerosol detector. Peaks (1), (2)
and (3) are photodegraded forms, peak (LDX) corresponds to lisdexamfetamine dimesylate.
Table 2 Results of peak purity of forced degradation study
using LC-UV (DAD).
Stress condition Peak Purity
Control sample 0.9999
Acid hydrolysis (1.0 M, reﬂux, silicone
bath at 100 C, 3 h)
0.9999
Alkaline hydrolysis (1.0 M, reﬂux, silicone
bath at 100 C, 3 h)
0.9999
Photolytic degradation (254 nm, 8 h) 1.0000
Oxidation (8% H2O2, reﬂux, silicone
bath at 100 C, 3 h)
0.9999
S1910 G. Carlos et al.paired because we used the same sample for UV and CAD
detectors since they are connected in series.
3. Results and discussion
3.1. Optimization of chromatographic conditions
Chromatographic conditions were optimized to provide two
simple, rapid and reliable HPLC methods to analyze LDX in
capsules using UV and charged aerosol detectors. Variousexperiments were carried out aiming to optimize both the sta-
tionary and mobile phases. Three kinds of stationary phases
were evaluated, C18, C8 and CN. The best resolution for
LDX peak was obtained with a Zorbax CN column
(250 mm · 4.6 mm, 5 lm). This is probably due to the fact that
LDX is a small polar amine drug and it was not satisfactory
retained in the C8 and C18 columns because of their nonpolar
characteristics. The CN column is a polar bonded-phase col-
umn packing used for normal or reversed-phase
chromatography.
During the optimization of the mobile phase, we started
from the following premise about CAD detector which could
inﬂuence its response: Volatile components and greater
organic content are required. This means that CAD is depen-
dent on the mobile-phase composition choice (Go´recki et al.,
2006; Vervoort et al., 2008). Thus, an increase in the organic
content of the mobile phase leads to an increase in the trans-
port efﬁciency of the nebulizer resulting in an increase of ana-
lyte amount delivered for detection and consequently higher
response is observed (Almeling et al., 2012; Cobb et al.,
2001; Cohen et al., 2012; Go´recki et al., 2006; Vervoort
et al., 2008). According to this premise, several mobile phases
were tried using various proportions of different aqueous
Table 5 Accuracy of methods for the determination of LDX
in capsules solutions prepared by standard addition.
Nominal Level % Recoverya % Meanb
%RSDc % RSDc
CAD 80 101.59 ± 0.21 100.50 ± 0.93
100 100.29 ± 0.91
120 99.63 ± 0.18
UV 80 100.11 ± 0.40 100.39 ± 0.39
100 100.22 ± 0.47
120 100.85 ± 0.11
a Mean of 3 replicates;
b Mean of 9 replicates;
c RSD= relative standard deviation.
Table 3 Requirements assessed for the LC-UV and LC-CAD
methods validation.
Parameter Statistical test Calculated value
LC-CAD LC-UV
Regression ANOVA
p-value1 4.72E20 1.09E24
ANOVA
F2 69,670.66 1,817,672.37
Lack-of-ﬁt ANOVA
p-value3 0.678 0.7
Autocorrelation DW (Durbin–Watson)
D-value4 2.24 1.56
Homoscedasticity Bartlett
p-value3 0.931 0.185
Normality test Kolmogorov–Smirnov
p-value >0.150 >0.150
Anderson–Darling
p-value 0.316 0.250
1 p< 0.05.
2 Fcritical;0.05 LC-CAD, LC-UV= 4.38.
3 p> 0.05.
4 Durbin–Watson test for residual autocorrelation with
dL = 1.22 and DU = 1.42.
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formate and ammonium acetate were tested (5, 10, 20, 25
and 40 mM), but ammonium formate showed to be more ade-
quate because of the improved detector UV sensitivity. LDX is
an ionizable drug, then to avoid more than one ionizable form,
the mobile phase was used at pH 4.0. The evaluated tempera-
tures (25 C, 30 C and 35 C) did not show differences in the
method. The mobile phase consisting of a mixture of 20 mM
ammonium formate at pH 4.0 (adjusted with formic acid) –
acetonitrile (50:50, v/v) was chosen because it allowed an ade-
quate run time, provided sufﬁcient selectivity and sensitivity,
and LDX was properly analyzed in the presence of its majorTable 4 Method repeatability/intermediate precision for lis-
dexamfetamine dimesylate.
Sample CAD UV
% Label claim % Label claim
Day 1 Day 2 Day 3 Day 1 Day 2 Day 3
1 100.34 99.99 99.83 99.73 100.37 99.94
2 100.36 100.39 99.27 100.78 100.19 99.56
3 99.87 99.85 99.81 100.87 100.18 100.25
4 99.72 100.13 99.62 100.41 100.68 99.58
5 99.58 100.46 99.44 99.63 99.88 100.33
6 101.30 99.81 99.32 100.24 100.33 100.22
Mean (6)a 100.20 100.11 99.55 100.28 100.27 99.98
% RSDb 0.63 0.27 0.24 0.52 0.26 0.31
Mean (18)c 99.95 100.18
% RSDb 0.47 0.39
a Mean of 6 replicates.
b RSD= relative standard deviation.
c Mean of 18 replicates.degradation products. The peak of LDX was well resolved
with retention time of 4.6 min.
3.2. Method validation
3.2.1. Speciﬁcity
Excipients present in LDX capsules did not interfere in the
analysis using both charged aerosol and UV detectors, as
shown in Fig. 2.
The speciﬁcity of the method was also determined by sub-
jecting standard and sample solutions to forced degradation
studies by acid and alkaline hydrolysis, oxidative, photolytic
and thermal conditions. Stress testing carried out with phar-
maceutical product gave the same results of LDX standard.
When LDX was subjected to heat, UV 352 nm, and 3%,
5% and 8% hydrogen peroxide at room temperature no addi-
tional peaks were observed nor a decrease of the area of LDX.
After acid and alkaline conditions, no degradation peaks were
detected but the area of LDX decreased when formic acid and
ammonium hydroxide (1 M, reﬂux, silicone bath at 100 C,
3 h) were used. For acid conditions a degradation extent of
5.5% for both CAD and UV was observed and alkaline condi-
tions showed a degradation extent of 5.3% and 5.2%, for UV
and CAD, respectively. Under oxidative conditions (8% H2O2,
reﬂux, silicone bath at 100 C, 3 h), the decrease in LDX peak
area was noticed (about 30%) and two additional peaks were
observed (3.8 and 4.0 min) in UV and charged aerosol detec-
tors as shown in Fig. 3. Under photolytic conditions
(254 nm, 8 h), three secondary peaks at retention times 3.2,
3.32 and 3.46 min were shown with UV detector (Fig. 4A)
and three peaks at retention times 3.38, 3.47 and 3.56 min were
observed with CAD (Fig. 4B). Peaks 1, 2 and 3 in
Fig. 4A and B could be considered the same, because the
detectors are connected in series. The decrease in LDX peak
area was about 22% in both detectors.
Considering that LDX was degraded only under strong
stress conditions, it can be considered as being very stable
under normal storage conditions.
LDX peak purity (standard solution) after stress conditions
was evaluated using a DAD detector and the same chromato-
graphic conditions. As shown in Table 2, no interference from
the impurities was observed at the detection wavelength
(207 nm). The active ingredient could be accurately measured
without interference, therefore the methods could be consid-
ered speciﬁcs and stability-indicating.
Figure 5 Pareto chart (Minitab 16) obtained for robustness assay of LDX capsule for the charged aerosol (A) and ultraviolet (B)
detectors.
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The calibration curves for LDX for UV and CAD were con-
structed by plotting the peak areas versus concentration. A lin-
ear correlation between the concentration and the detector
response was found in the 70–130 lg mL1 range for both
detectors. Although CAD is a concentration-dependent detec-
tor, the relationship between the amount of analyte and signal
could not be directly linear over a wide concentration range
(Dixon and Peterson, 2002; Go´recki et al., 2006; Vehovec
and Obreza, 2010). However, there are reports in the literature
describing that the response over a narrow range is linear
(Bernardi et al., 2013; Holzgrabe et al., 2011; Stypulkowska
et al., 2013), corroborating the linearity found in our narrow
range. ANOVA was used to conﬁrm the linearity. The correla-
tion coefﬁcient was 0.9999 for UV and 0.9997 for CAD and
the representative linear regression equation was
y= 0.3758x  2.1089 for UV and y= 0.1339x  2.1802 for
CAD. ANOVA results demonstrated signiﬁcant linear regres-
sion (p< 0.05) and the value of Fcalculated > Fcritical (95% con-
ﬁdence interval) for both detectors demonstrates thesigniﬁcance of the regression and conﬁrms the linearity over
the working range studied.
Residuals were evaluated with respect to the normality
(Kolmogorov–Smirnov and Anderson–Darling tests), no auto-
correlation in regression residuals (Durbin–Watson statistic
test) and the homogeneity (Bartlett’s test). Residual results
showed that calibration curves of LDX for CAD and UV fol-
lowed a normal distribution, were independent and
homoscedastic (Table 3).
Limit of detection (LOD) and quantiﬁcation (LOQ) were
calculated using the linear equations presented above. LOD
calculated was 0.24 and 1.89 lg mL1, respectively, for UV
and CAD, and the LOQ calculated was 0.78 and
6.3 lg mL1, respectively, for UV and CAD which indicates
the adequate sensitivity of the methods.3.2.3. Precision and accuracy
The results for repeatability (intraday) and intermediate preci-
sion (interday) of methods are presented in Table 4. They were
Table 6 Robustness assay results of LDX capsule for the
methods LC-CAD and LC-UV.
Experiments % Label claim
UV CAD
1 100.56 99.76
2 100.21 99.53
3 100.15 100.77
4 99.49 99.93
5 99.93 99.84
6 100.11 100.55
7 100.84 100.06
8 99.70 99.39
9 99.47 99.53
10 100.24 100.68
11 100.29 100.27
12 99.91 99.32
Mean (12)a 100.07 99.97
% RSDb 0.41 0.50
a Mean of 12 replicates;
b RSD= relative standard deviation.
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CAD and UV (value 62.0%) (ICH, 2005).
The results obtained for accuracy are presented in Table 5.
LDX mean recovery for the three levels was 100.39 ± 0.39 for
UV and 100.50%± 0.93 for CAD. Based on these ﬁndings the
methods showed to be precise and accurate.
3.2.4. Robustness
Robustness response is showed through a Pareto chart of the
effects that determine the magnitude and the importance of
each effect. The chart displays in the bars the absolute value
of the effects and draws a vertical line on the chart that repre-
sents the critical t-value for an a of 0.05. The effect is not sig-
niﬁcant when its bar not overtakes the vertical line. As shown
in Fig. 5, none of the factors studied has a signiﬁcant effect
(a= 0.05) on the determination of the LDX with UV and
CAD. Analysis of Pareto chart allowed us to observe the
robustness of the method, since the factors did not present sig-
niﬁcant effect on the quantiﬁcation of LDX in all the experi-
mental conditions in both methods. The assay for LDX was
99.97%± 0.50 for LC-CAD and it was 100.07%± 0.41 for
LC-UV as shown in Table 6.
3.3. Comparison of methods
The statistical method of comparison uses the mean of preci-
sion of each method. Through the Table 7, it can be seen thatTable 7 Comparison of LDX through the LC-UV and LC-
CAD methods.
Method Assay (%)a RSDb (%)
UV 100.18 0.39
CAD 99.95 0.49
p-value p> 0.05 fcalculated = 1.71 < fcritical = 2.10
a Mean of 18 replicates.
b RSD= relative standard deviation.the results of both methods, UV and CAD, show a non-
signiﬁcant difference (p> 0.05).
4. Conclusions
HPLC methods using charged aerosol and UV detectors pro-
vided good results in terms of linearity, accuracy, precision,
limit of detection and quantiﬁcation, robustness and speci-
ﬁcity, without any interference from excipients as well as
degradation products. Both methods were adequately vali-
dated and provide an appropriate quality control tool for rou-
tine analysis and stability assays of LDX in capsule dosage
forms. The results show that the UV and CAD methods devel-
oped and validated are interchangeable with each other over
the concentration range studied.
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